Cell-free DNA (cfDNA) sequence analysis to screen for fetal aneuploidy can incidentally detect maternal cancer. Additional data are needed to identify DNA-sequencing patterns and other biomarkers ...

Cell-free DNA (cfDNA) can act as a powerful biomarker for cancer research, from disease onset to therapy selection and minimal residual disease (MRD) measurement. Next-generation sequencing (NGS) has ...

In 107 patients, 48.6% of those who received unusual or nonreportable clinical cfDNA-sequencing results had an occult cancer, reported Diana W. Bianchi, MD, of the Eunice Kennedy Shriver National ...

Field trial further shows consistent extraction and sequencing on non-Illumina platform A field trial of the kit was conducted in a clinical setting with more than 300 samples.

The NIH's IDENTIFY study aims to better understand abnormal cfDNA test results that may signal possible cancers. Out of the participants, 52 were diagnosed with previously undetected cancer, or 48.6%.

Turriff, A. E., et al. (2024) Prenatal cfDNA sequencing and incidental detection of maternal cancer. New England Journal of Medicine. doi.org/10.1056/NEJMoa2401029.

HealthDay News — Almost half of pregnant or postpartum women with unusual or nonreportable clinical cell-free (cf)DNA-sequencing results have occult cancer, according to a study published in the ...

Minimal residual disease (MRD) is a term referring to the small populations of cancer cells that may remain in the body following primary treatment. Early and accurate MRD detection is important for ...

In the independent validation cohort, the test achieved a sensitivity of 87.4% and a specificity of 97.8%. Sensitivity for early-stage cancers was 79.3% for stage I and 86.9% for stage II ...

Enzymatic conversion–mediated whole-methylome sequencing was applied to plasma cfDNA samples extracted from 168 patients with ESCC and 251 noncancer controls. ESCC characteristic cfDNA methylation, ...